Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study-Reference-Cited by-同舟云学术

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

Published:2009-03 Issue:3 Volume:10 Page:247-257
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Cohen Ezra EW,Davis Darren W,Karrison Theodore G,Seiwert Tanguy Y,Wong Stuart J,Nattam Sreenivasa,Kozloff Mark F,Clark Joseph I,Yan Duen-Hwa,Liu Wen,Pierce Carolyn,Dancey Janet E,Stenson Kerstin,Blair Elizabeth,Dekker Allison,Vokes Everett E

Publisher

Elsevier BV

Subject

Oncology

Reference38 articles.

1. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population;Pisani;Int J Cancer,2002

2. Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors;Ahmed;Curr Cancer Drug Targets,2007

3. Platinum-based chemotherapy plus cetuximab in head and neck cancer;Vermorken;N Engl J Med,2008

4. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck;Cohen;J Clin Oncol,2006

5. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells;Ciardiello;Clin Cancer Res,2000

Cited by 244 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer;Oral Oncology Reports;2024-09

2. Extracellular vesicle-bound VEGF in oral squamous cell carcinoma and its role in resistance to Bevacizumab Therapy;Cancer Cell International;2024-08-23

3. Anti-angiogenic therapy in head and neck squamous cell carcinoma - current limitations and future directions;Vessel Plus;2024-06-24

4. Bioinformatic analysis and experimental validation of cuproptosis-related LncRNA as a novel biomarker for prognosis and immunotherapy of oral squamous cell carcinoma;Hereditas;2024-02-27

5. Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer—A Step before Anakoinosis-Based Personalized Treatment;Cancers;2023-08-24